Bulleted statement. 22
Most of the literature on TOPFA for congenital heart defects includes single-center hospital-based 23 studies. Moreover, few studies have evaluated both socioeconomic and clinical factors that could 24 be associated with the risk of TOPFA for congenital heart defects. 25
Using population-based data, we found that, in addition to severity of congenital heart defects, 26 early prenatal diagnosis and maternal characteristics are highly associated with the probability of 27 TOPFA for isolated congenital heart defects. Congenital heart defects (CHD) are the most frequent congenital anomalies.
1 Progress in fetal 63 ultrasonography has conducted to an increase in the overall proportion of congenital 64 malformations, and in particular CHD, that are prenatally diagnosed. The most severe cases of 65 CHD can be accurately diagnosed during fetal life.
2-4 Ultrasonography screening for CHD at 13/14 66 weeks of gestation has shown to have good performances and has been proposed to be routinely 67 performed in low-risk population. 5 In case of positive screening, a more detailed scan must be 68 performed by a pediatric cardiologist in the beginning of the second trimester. 6 In high risk 69
population, a specialized scan should be offered in first trimester. 7 The overall effect of prenatal 70 diagnosis on the outcome of fetuses with CHD is difficult to evaluate due to higher severity of 71 cases that are prenatally diagnosed. 8 Nevertheless, the beneficial effect of prenatal diagnosis on 72 morbidity and mortality has been shown for certain CHD such as transposition of great arteries or 73 coarctation of the aorta. 2, 9, 10 
74
For the most severe CHD, termination of pregnancy for fetal anomaly (TOPFA) following prenatal 75 diagnosis may be an option to discuss with parents. 6, 11, 12 Previous studies have shown that timing 76 and accuracy of prenatal diagnosis, existence of associated anomalies, available treatment options 77 and prognosis are factors associated with decision-making regarding TOPFA in case of CHD. 6, 12, 13 78 However, most studies have examined TOPFA for CHD with single-center hospital-based 79 data 11,13,14 and few population-based studies exist regarding TOPFA for CHD. 2, 3, 15 Moreover, few 80 studies have evaluated both socioeconomic and clinical factors that could be associated with the 81 risk of TOPFA for CHD. 82
Using population-based data from the Paris Registry for Congenital Malformations, we 1) 83 examined the proportion of TOPFA and gestational age at TOPFA for all CHD and categories of 84 CHD and 2) assessed the role of socioeconomic and clinical factors associated with TOPFA andgestational age at TOPFA for cases of "isolated" CHD excluding ventricular septal defects (i.e., 86 "major" CHD with no other associated anomalies). 87
MATERIAL AND METHODS 88

Data 89
We used data from the Paris Registry for Congenital Malformations which registers all cases of 90 birth defects and chromosomal anomalies among live-borns, still-borns (≥22 weeks of gestation), 91 and TOPFA at any gestational age. The Registry covers the population of women who live in 92
Greater Paris area (Paris and its surrounding suburb) and deliver or have a pregnancy termination 93 in a Parisian maternity unit. The annual number of deliveries in our population is about 38 000. 94
The Paris Registry is a member of the European Network 
Methods
106
We conducted an observational study to i) describe the proportion of TOPFA after prenatal 107 diagnosis and gestational age at TOPFA and ii) assess predictors associated with the risk (odds) of 108 TOPFA and gestational age at TOPFA. 109
Proportions of TOPFA and gestational age at TOPFA were estimated for the following categories: 110 i) all CHD combined, ii) all isolated CHD, iii) isolated CHD-ventricular septal defects (VSD)excluded; the latter category was constituted in order to represent major isolated CHD that often 112 requires intervention , iv) CHD associated with chromosomal anomalies and v) CHD associated 113 with malformations of other systems. 114
Predictors of the odds of TOPFA were assessed for isolated CHD-VSD excluded. Variables 115 considered as predictors were maternal characteristics (age, occupation, geographic origin and 116 gravidity), clinical characteristics (nuchal translucency, intra-uterine growth retardation (IUGR), 117 gestational age at prenatal diagnosis, gestational age at TOPFA, and category of CHD) and year of 118 TOPFA. Maternal age was coded in three categories (≤ 34, 35-37, ≥38) IUGR was as noted in medical records and coded in two categories (no/yes). Gestational age at 127 prenatal diagnosis was dichotomized in gestational age ≤ 22 and >22 weeks, as 22 weeks is the 128 recommended term for 2nd trimester scan in France. Gestational age at TOPFA was analyzed as a 129 continuous variable. Isolated cases of CHD were classified into 4 subcategories by a pediatric 130 cardiologist (T.B.) based on the diagnosis recorded in the Registry database: i) functionally 131 univentricular CHD, ii) so-called conotruncal CHD, iii) complex CHD (at least two cardiac defects 132 combined excluding VSD) and iv) other CHD. 133
134
Statistical analyses 135
Data were analyzed using standard descriptive statistics (mean, standard deviation (SD), and 136 frequency). Chi-square test, or Fisher's exact test when appropriate, and ANOVA test were used 137 for univariate analyses of the differences between groups. The associations between clinical and 138 socioeconomic factors and the odds of TOPFA were assessed using logistic regression models. 139
Observations with missing values were excluded from the multivariate analyses. The statistical 140 significance level was set at α = 0.05. All analyses were done with Stata 10 software (Statacorp, 141 TX, USA). 142
143
RESULTS
144
During the study period, 1465 cases of CHD were registered, among which 66% (n=968) were 145 isolated CHD, 16% (n=230) were CHD associated with chromosomal anomalies and 18% (n=267) 146 with anomalies of other systems (including genetic syndromes). VSD accounted for half of the 147 cases of isolated CHD (51%, n = 495). 148
Gestational age at prenatal diagnosis was missing for 0.4% of fetuses. There were no missing data 149 for the outcome of the pregnancy (live-birth, still-birth, TOPFA). Maternal occupation and nuchal 150 translucency were missing for 8% of cases. For the other variables, data were missing for less than 151 1% of fetuses. 152 Table 1 The highest proportion of TOPFA was observed for CHD associated with chromosomal anomalies 159 (82%, 148/182). CHD associated with chromosomal anomalies accounted for 45% of cases of 160 TOPFA (148/325). Proportion of TOPFA for isolated CHD -VSD excluded was 27% (74/274). 161
Among those 74 cases of TOPFA for isolated CHD -VSD excluded, hypoplastic left heart 162 syndrome accounted for half (51%, n=38). 163
Overall, the mean gestational age at prenatal diagnosis was 20.4 weeks (SD 0.26) for the study 164 population (Table 2 ). Mean gestational age at prenatal diagnosis was lowest for cases associated 165 with chromosomal anomalies (19.1, SD 0.38) and highest for isolated CHD -VSD excluded (21.9, 166 SD 0.39). The mean gestational age at TOPFA was 23.2 weeks (SD 0.29) for the study population 167 (Table 2 ). The average gestational age at TOPFA was lowest for CHD associated with 168 chromosomal anomalies (21.7, SD 0.45) and highest for isolated CHD -VSD excluded (24.8, SD 169 0.46). The mean duration between prenatal diagnosis and TOPFA was 2.8 weeks and was similar 170 for all subcategories of CHD. More than half (57%) of TOPFA for CHD associated with 171 chromosomal anomalies were performed before 22 weeks of gestation vs. 17% for isolated CHD -172 VSD excluded. We did not find a significant time trend in the gestational age at TOPFA over the 173 study period. 174 Table 3 summarizes the univariate analyses of the association of TOPFA for isolated CHD -VSD 175 excluded with maternal characteristics and clinical factors. TOPFA was significantly less frequent 176 for mothers of African origin (11% vs. 33% for mother of French origin and 28% for women of 177 other origin, p=0.003). TOPFA was significantly more frequent for CHD diagnosed before 22 178 weeks of gestation (42% vs. 17% for CHD diagnosed after 22 weeks, p<0.001), for functionally 179 univentricular CHD and complex CHD (60% and 34 % respectively vs. 21% for conotruncal CHD 180 and 11% for other CHD, p<0.001). No statistically significant associations were observed for the 181 other factors, although TOPFA tended to be more frequent in case of IUGR (50% vs. 26%, 182 p=0.09). There was no significant timr trend in the odds of TOPFA during the study period. 192 Table 5 summarizes the results of the univariate analyses of predictors of mean gestational age at 193 TOPFA. Sample sizes were relatively small and no statistically significant associations were 194 observed. In particular maternal characteristics were not significantly associated with gestational 195 age at TOPFA whereas an increased nuchal translucency measurement tended to be associated with 196 a lower gestational age at TOPFA although the association was not statistically significant 197 (p=0.13). 198
DISCUSSION 200
Using population-based data from the Paris Registry for Congenital Malformations, we found that 201 the overall rate of termination of pregnancy for fetal anomaly (TOPFA) for cases with congenital 202 heart defects (CHD) prenatally diagnosed was 46%. The highest probability of TOPFA was 203 observed for CHD associated with chromosomal anomalies (82%). A prenatal diagnosis before 22 204 weeks of gestation was associated with a 3.2-higher odds of TOPFA for isolated CHD -VSD 205 excluded. Maternal occupation was not independently associated with the probability of TOPFA. 206
However, mothers of African origin had a 10 fold-lower odds of TOPFA than women of French 207
origin. 208
It is difficult to know the extent to which our results may be generaliseable to other countries. 209
France represents a particular context for prenatal diagnosis and TOPFA as it pursues an active and 210 highly codified policy of prenatal diagnosis. In contrast to many European countries, TOPFA is 211 authorized in France regardless of gestational age for incurable fetal diseases or life-threatening 212 maternal conditions. 20 Proportions of prenatal diagnosis and TOPFA, in particular for CHD, tend 213 to be higher in France as compared to those observed in other countries 1,15,16 even though 214 differences in the post-natal diagnosis and the period of registration of cases in the postnatal period 215 across countries complicate the interpretation of observed differences in the proportion of prenatal 216 diagnosis for CHD in different countries. 217
We observed a lower proportion of TOPFA for isolated CHD as compared to CHD associated with 218 chromosomal anomalies or anomalies of other systems, which is consistent with the data from the 219 European surveillance of congenital anomalies (Eurocat) network of registries of congenital 220 anomalies. 4, 21 We also observed that the risk of TOPFA was significantly higher for functionally 221 univentricular CHD, which is due to the fact that the outcomes for functionally univentricular 222 CHD remain poor. 22, 23 Socioeconomic factors are known to be associated with the likelihood of TOPFA for chromosomal 224 anomalies, in particular Down syndrome. [24] [25] [26] [27] This association has been little studied in the specific 225 case of CHD. 27 In a hospital-based study, Zyblewski et al. 13 did not find an association between 226 socioeconomic factors and TOPFA. We found that maternal geographic origin, but not occupation, 227 was strongly associated with the risk of TOPFA for isolated CHD. Access to information about 228 prenatal diagnosis and TOPFA and parental decision making for chromosomal anomalies have 229 been shown to be influenced by preferences and cultural factors 26, 28 , although the barriers to 230 effective access to full information may also include language barrier since interpreters are often 231 not available. The same association between TOPFA and cultural factors may exist for isolated 232 CHD. We did not observe an association between maternal age and the probability of TOPFA for 233 isolated CHD, suggesting that the overall higher rates of TOPFA for CHD in older women were 234 due to the higher proportions of associated chromosomal anomalies. Prenatal diagnosis and 235 TOPFA occurred earlier in case of CHD associated with chromosomal anomalies. 28, 29 This may 236 have been in part due to an increased nuchal translucency measured in the first trimester which is 237 more likely to occur for both chromosomal anomalies and certain CHD. It is also possible that 238 even in the absence of an increased nuchal translucency, cytogenetic studies conducted after 239 prenatal diagnosis of a CHD diagnosed earlier in pregnancy were more likely to reveal an 240 associated chromosomal anomaly. 241
The average interval between prenatal diagnosis and TOPFA was similar (two weeks) for both 242 isolated CHD and CHD associated with chromosomal anomalies and was consistent with other 243 studies. 4, 29 This interval corresponds to the time necessary for a multidisciplinary discussion and 244 for parents to make their decision. 245
The proportion of TOPFA in fetuses with CHD has been shown to be higher when prenatal 246 diagnosis occurs earlier. 4, 5, 12 We also found that isolated CHD -VSD excluded diagnosed before 247 22 weeks had a 3.2-fold higher odds of TOPFA in comparison to those diagnosed later. TOPFA 248 may indeed be more easily accepted by families at an earlier gestational age. 4 In addition, CHD 249 diagnosed earlier may have been on average more severe (associated with poorer prognosis) and 250 hence be more likely to be a candidate for TOPFA. Even though we partially took into account 251 severity of CHD in our analyses, a residual effect of severity as one explanation for the association 252 between earlier timing of prenatal diagnosis and probability of TOPFA cannot be excluded. 253
For isolated CHD -VSD excluded, gestational age at TOPFA tended to be lower in case of 254 abnormal nuchal translucency. Indeed, a more detailed examination of fetal heart is usually 255 performed after an abnormal nuchal translucency measurement on first trimester ultrasonography 256 and may therefore conduct to the earlier diagnosis of a CHD.
30,31 257
Our study has certain limitations. Due to small sample sizes, confidence intervals were fairly wide 258 indicating the limited precision of our estimates. We did not adjust for paternal characteristics due 259 to a high frequency of missing data. Nevertheless, paternal characteristics are strongly correlated 260 with maternal characteristics and are therefore, at least partially, taken into account by maternal 261 adjustment. Data were complete for pregnancy outcome and there were few missing data for the 262 factors included in the analyses. Bias in our estimates due to missing data is therefore unlikely. 263 However, residual bias or residual confusion due to missing data or confounding factors not taken 264 into account in this study cannot be excluded. The strengths of our study are a large sample size 265 and population-based data. 266
We explored specific associations that may exist between the risks of TOPFA and different 267 categories of CHD defined a priori based on anatomic and/or clinical criteria and classified by a 268 pediatric cardiologist. A caveat that needs to be considered is that our criteria for defining these 269 categories can be arguable. Moreover, alternative and more detailed groupings exist 32, 33 , which 270 may provide additional information for estimating the probability of TOPFA for CHD. However,our results suggest that specific associations exist between the categories of CHD as defined in our 272 study and the probability of TOPFA without necessarily implying that the categories investigated 273 in our study are the most appropriate ones to use in this setting. 274
Diagnostic bias may have occurred as not all fetuses with a prenatally diagnosed CHD resulting in 275 TOPFA had a fetal pathology examination. Therefore, in these cases ascertainment of CHD was 276 based only on prenatal findings. Nevertheless, these cases represented a minority of the overall 277 study population. 278 279
CONCLUSION. 280
In conclusion, TOPFA occurred for 27% of isolated CHD -VSD excluded that were prenatally 281 diagnosed, 82% of CHD associated with chromosomal anomalies and 53% of CHD associated 282 with anomalies of other systems. Prenatal diagnosis of isolated CHD -VSD excluded before 22 283 weeks of gestation was associated with a 3.2-fold higher odds of TOPFA. Women of African 284 origin had a 10-fold lower odds of TOPFA than women of French origin. The categories of CHD 285 reflecting its severity were also significantly associated with the risk of TOPFA for isolated CHD -286 VSD excluded. Gestational age at TOPFA tended to be earlier in fetuses with an abnormal nuchal 287 translucency. Timing of TOFPA was explained essentially by timing of prenatal diagnosis and the 288 time interval between prenatal diagnosis and TOPFA appeared to be essentially constant for all the 289 clinical and socioeconomic categories included in our study. 290
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